EX-10.18
Talawar Tx Inc.
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.
ANTIBODY DISCOVERY AND OPTION AGREEMENT
by and between
KHANDA THERAPEUTICS LP
and
TALAWAR TX INC.
Dated as of June 1, 2026
Page 1
CONFIDENTIAL
ANTIBODY DISCOVERY AND OPTION AGREEMENT
THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is entered into and effective as of June 1, 2026 (the “Effective Date”), by and between:
Khanda Therapeutics, L.P., a Delaware limited partnership with its registered office at [*] (“Khanda”), and
Talawar Tx Inc, a Delaware corporation with its registered office at [*] (“Talawar”).
Khanda and Talawar are also referred to herein individually as a “Party”, or collectively as the “Parties.”
RECITALS
WHEREAS, Khanda discovers and develops proprietary Antibodies (as defined below) against therapeutically relevant Targets (as defined below);
…